For the next few weeks, due to internal governance issues, when you request the MFIA M. hyopneumoniae test, we will use our MFIA PRRSV-M. hyopneumoniae test.
You will be billed at the same price as the MFIA M. hyopneumoniae test alone, but you will receive the PRRSV results at no additional charge.
If you do not wish to receive results for the PRRSV, please specify this in your request.
This offer will allow you to become familiar with the MFIA PRRSV test.
The MFIA (Multiplexed Fluorescing Immuno Assay) uses several “sets” of microbeads (5 µm) to which different antigens are attached (one type of antigen per type of microbead).
The reaction between antigen-covered beads and sera to be tested occurs in the wells of a 96-well microplate.
At the outcome of the reaction, the plate is read in a device that determines the type of microbead that reacted (or not) with the samples and the intensity of each reaction.
Finally, the results are expressed for each antigen as S/P ratios, S being the fluorescence intensity of the sample and P that of the positive control.
Note that a MFIA 5-plex test for PRRSV type 1- PRRSV type 2-APP2-APP6-APP12 has been used for about 3 years in Denmark by the SEGES diagnostic laboratory (www.seges.dk/en)
In fact, it became their first-line test for PRRSV serology, with the Idexx ELISA test being used as the confirmatory test. Over the past 3 years, they have conducted several thousand tests.
The performance of the MFIA PRRSV test is comparable to that of Idexx ELISA, with the additional ability to differentiate between PRRSV type 1 or type 2 infections.
This is not important in Canada, but it is important in countries where both types of strains, wild and/or vaccine, circulate.
Results obtained during the first months of use were presented at the AAVLD Annual Meeting in 2017.
Please feel free to contact us for further information.